Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

Recordati continues clinical development of BPH Rx

Feb. 13, 1998

Controlled-release oxybutynin to be marketed in Europe by Synthelabo

Feb. 2, 1998

Synaptic develops selective human alpha1A-receptor antagonists

Feb. 2, 1998

RTX enters phase II for urge incontinence

Jan. 27, 1998

FDA accepts RenaGel NDA for filing

Jan. 22, 1998

New urinary incontinence product from Biomatrix cleared for clinical trials

Jan. 12, 1998

Synaptic, Merck & Co. extend BPH research agreement

Jan. 5, 1998

Cephalon describes new indolocarbazoles for prostate disorders

Dec. 30, 1997

NDA filed for extended-release Ditropan formulation

Dec. 29, 1997

Bladder efficacy demonstrated for KATP channel opener

Dec. 19, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...